Emcure Pharmaceuticals Ltd.
EMCURE
Rang in aandelen
#4306
Emcure Pharmaceuticals Limited is committed to providing high-quality,... Emcure Pharmaceuticals Limited is committed to providing high-quality, cost-effective healthcare solutions to a global market. The company boasts a diverse product lineup spanning numerous medical fields, such as women's health (gynecology), anti-infectives, pain relief, nutritional supplements (vitamins, minerals, and nutrients), hematology, oncology, respiratory treatments, HIV antivirals, gastrointestinal remedies, anti-diabetics, neurological medications, and cardiovascular therapies. Notable brand names under their umbrella include Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym. Founded in 1981, Emcure Pharmaceuticals Limited is headquartered in Pune, India.
Aandeelprijs
$19.06
Marktkapitalisatie
$3.62B
Verandering (1 dag)
-1.83%
Verandering (1 jaar)
20.50%
Land
IN
Handel Emcure Pharmaceuticals Ltd. (EMCURE)
Categorie
Healthcare
P/B-ratio voor Emcure Pharmaceuticals Ltd. (EMCURE)
P/B-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Emcure Pharmaceuticals Ltd. is de huidige P/B-ratio (TTM) 0. Eind 2026 had het bedrijf een P/B-ratio van 0.
P/B-ratiohistoriek voor Emcure Pharmaceuticals Ltd. van 2025 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2025 | 4.53 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | - |
IN
|
